Treatment of toxoplasmosis: historical perspective, animal models, and current clinical practice
IR Dunay, K Gajurel, R Dhakal… - Clinical microbiology …, 2018 - Am Soc Microbiol
Primary Toxoplasma gondii infection is usually subclinical, but cervical lymphadenopathy or
ocular disease can be present in some patients. Active infection is characterized by …
ocular disease can be present in some patients. Active infection is characterized by …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
JW Baddley, F Cantini, D Goletti… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
M Reinwald, JT Silva, NJ Mueller, J Fortún… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
KL Winthrop, X Mariette, JT Silva, E Benamu… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated …
AY Classen, L Henze, M von Lilienfeld-Toal… - Annals of …, 2021 - Springer
Hematologic and oncologic patients with chemo-or immunotherapy-related
immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii …
immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
G Redelman-Sidi, O Michielin, C Cervera, C Ribi… - Clinical Microbiology …, 2018 - Elsevier
Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …
[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
COVID-19 in patients with rheumatological diseases treated with anti-TNF
CA Brito, JG Paiva, FN Pimentel… - Annals of the …, 2021 - ard.bmj.com
We have read with great interest the recent article from Silva et al about the clinical course of
COVID-19 in rheumatic disease. 1 In this matched cohort study of patients with COVID-19 …
COVID-19 in rheumatic disease. 1 In this matched cohort study of patients with COVID-19 …
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients
BW Teh, M Mikulska, D Averbuch… - The Lancet Infectious …, 2024 - thelancet.com
Patients can be immunocompromised from a diverse range of disease and treatment factors,
including malignancies, autoimmune disorders and their treatments, and organ and stem …
including malignancies, autoimmune disorders and their treatments, and organ and stem …